HOUT-28. OFF-LABEL USE OF PD-1 BLOCKADE WITH OR WITHOUT BEVACIZUMAB CONFERS ONLY LIMITED CLINICAL BENEFIT IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.